These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Patel K; Amthor H Neuromuscul Disord; 2005 Feb; 15(2):117-26. PubMed ID: 15694133 [TBL] [Abstract][Full Text] [Related]
13. Emerging strategies for cell and gene therapy of the muscular dystrophies. Muir LA; Chamberlain JS Expert Rev Mol Med; 2009 Jun; 11():e18. PubMed ID: 19555515 [TBL] [Abstract][Full Text] [Related]
14. Genome- and Cell-Based Strategies in Therapy of Muscular Dystrophies. Saada YB; Dib C; Lipinski M; Vassetzky YS Biochemistry (Mosc); 2016 Jul; 81(7):678-90. PubMed ID: 27449614 [TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle in health and disease. Morgan J; Partridge T Dis Model Mech; 2020 Feb; 13(2):. PubMed ID: 32066552 [TBL] [Abstract][Full Text] [Related]
16. Current advances in cell therapy strategies for muscular dystrophies. Negroni E; Vallese D; Vilquin JT; Butler-Browne G; Mouly V; Trollet C Expert Opin Biol Ther; 2011 Feb; 11(2):157-76. PubMed ID: 21219234 [TBL] [Abstract][Full Text] [Related]
17. Perspectives on hiPSC-Derived Muscle Cells as Drug Discovery Models for Muscular Dystrophies. Abati E; Sclarandi E; Comi GP; Parente V; Corti S Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502539 [TBL] [Abstract][Full Text] [Related]
18. Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications. Serrano AL; Muñoz-Cánoves P Semin Cell Dev Biol; 2017 Apr; 64():181-190. PubMed ID: 27670721 [TBL] [Abstract][Full Text] [Related]
19. [CRISPR-Cas9 for muscle dystrophies]. Ballouhey O; Bartoli M; Levy N Med Sci (Paris); 2020 Apr; 36(4):358-366. PubMed ID: 32356712 [TBL] [Abstract][Full Text] [Related]